drugset / Trial / NCT01905683

Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy

NCT01905683 ↗

Phase 3 Completed 370 enrolled Merz Pharmaceuticals GmbH
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg(s) or of leg(s) and one arm are safe in treating children/adolescents (age 2-17 years) long-term with increased muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy.

Timeline

Start
2013-08
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 16 iu/kg Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 20 iu/kg Intramuscular